Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Bicara Therapeutics Inc. (NASDAQ:BCAX) will release earnings for its fourth quarter before the opening bell on Monday, March 30.

Analysts expect the Boston, Massachusetts-based company to report a quarterly loss of 65 cents per share, versus a loss of 39 cents per share in the year-ago period, according to Benzinga Pro.

On March 4, Bicara Therapeutics announced inducement grant under Nasdaq Listing Rule 5635(c)(4).

Bicara Therapeutics shares fell 1.6% to trade at $18.62 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying BCAX stock? Here’s what analysts think:

Photo via Shutterstock